Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Oncol
Egile Nagusiak: Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2020
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://ncbi.nlm.nih.gov/pubmed/32411240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7131802
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak